<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01186692</url>
  </required_header>
  <id_info>
    <org_study_id>D03909</org_study_id>
    <nct_id>NCT01186692</nct_id>
  </id_info>
  <brief_title>Melody® Transcatheter Pulmonary Valve Post-Approval Study</brief_title>
  <official_title>Implantation of the Medtronic Melody Transcatheter Pulmonary Valve (TPV) in Patients With Dysfunctional Right Ventricular Outflow Tract (RVOT) Conduits: A Post-Market Approval Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiovascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm the short-term hemodynamic effectiveness results
      achieved by real-world providers are equivalent to the historical control established in the
      IDE study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2010</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acceptable TPV Hemodynamic Function at Six Months After Successful TPV Implantation</measure>
    <time_frame>6 months</time_frame>
    <description>Acceptable TPV hemodynamic function at six months after successful TPV implantation is determined as a composite of the following:
Mean RVOT gradient is less than or equal to 30 mmHg as measured by CW Doppler, and
Severity of pulmonary regurgitation is less than moderate by Doppler echocardiography, and
Free from RVOT conduit reoperation or catheter re-intervention at six months after TPV implantation.
The endpoint is defined as the percentage of subjects with acceptable TPV hemodynamic function at six months after Melody valve implantation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>6 Months</time_frame>
    <description>Procedural success is defined as a composite of the following:
The TPV is fixated within the desired location, and
The RV-PA peak-to-peak gradient measured in the catheterization lab after TPV implantation is less than 35 mmHg, and
There is no more than trivial pulmonary regurgitation by angiography
The subject is free from explantation of the TPV at 24 hours post-implant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Procedural Adverse Events</measure>
    <time_frame>6 Months</time_frame>
    <description>A procedure-related event is defined as an event that is associated with the implant procedure by the chronology or physiology and was caused by the implant procedure (e.g. rupture of the conduit or damage to an intra-cardiac or intravascular structure by the delivery system).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Device-related Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <description>A device-related event is defined as an event that is associated with the TPV by the chronology or physiology and was caused by the the TPV (e.g. embolization of the TPV and any adverse events which follow).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in NYHA Functional Classification</measure>
    <time_frame>6 Months</time_frame>
    <description>Change in NYHA functional class from pre-implant to 6 month post-implant</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">131</enrollment>
  <condition>Dysfunctional Right Ventricular Outflow Tract (RVOT) Conduit</condition>
  <arm_group>
    <arm_group_label>Melody TPV Implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Melody® Transcatheter Pulmonary Valve implanted into a dysfunctional RVOT Conduit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Melody® Transcatheter Pulmonary Valve</intervention_name>
    <description>Transcatheter Pulmonary Valve replacement Transcatheter valve implantation into a RVOT conduit in patients with complex congenital heart defects where the conduit has become dysfunctional and where the patient needs invasive intervention.</description>
    <arm_group_label>Melody TPV Implant</arm_group_label>
    <other_name>Melody Transcatheter Pulmonary Valve</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Existence of a full (circumferential) RVOT conduit that was equal to or greater than
             16 mm in diameter when originally implanted

          -  Dysfunctional RVOT conduits with a clinical indication for intervention (regurgitation
             ≥ moderate regurgitation, Stenosis: mean RVOT gradient ≥ 35 mmHg)

        Exclusion Criteria:

          -  Implantation in the aortic or mitral position

          -  Venous anatomy unable to accommodate a 22-fr size introducer sheath

          -  Obstruction of the central veins

          -  Clinical or biological signs of infection including active endocarditis

          -  Unwilling or unable to provide written informed consent or comply with the follow-up
             requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaqueline Kreutzer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of University of Pittsburgh Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rady Children's Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advocate Hope Children's Hospital</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <zip>60453</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CS Mott Children's Hospital, University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Medical Center Dallas, UT Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Children's Medical Center, University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2010</study_first_submitted>
  <study_first_submitted_qc>August 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2010</study_first_posted>
  <results_first_submitted>September 30, 2016</results_first_submitted>
  <results_first_submitted_qc>October 31, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 26, 2016</results_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Enrolled</title>
          <description>All subjects enrolled (n=131)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not Catheterized</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Futher testing contraindicated implant</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Enrolled Cohort</title>
          <description>All subjects enrolled.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="131"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.1" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Acceptable TPV Hemodynamic Function at Six Months After Successful TPV Implantation</title>
        <description>Acceptable TPV hemodynamic function at six months after successful TPV implantation is determined as a composite of the following:
Mean RVOT gradient is less than or equal to 30 mmHg as measured by CW Doppler, and
Severity of pulmonary regurgitation is less than moderate by Doppler echocardiography, and
Free from RVOT conduit reoperation or catheter re-intervention at six months after TPV implantation.
The endpoint is defined as the percentage of subjects with acceptable TPV hemodynamic function at six months after Melody valve implantation.</description>
        <time_frame>6 months</time_frame>
        <population>The implanted &gt;24 hours cohort consists of all subjects who had a Melody TPV implanted which remained implanted for greater than 24 hours. Of this population those with evaluable echo data at 6 months post implant were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Implanted &gt;24 Hours Cohort</title>
            <description>The implanted &gt;24 hours cohort consists of all subjects who had a Melody TPV implanted which remained implanted for greater than 24 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Acceptable TPV Hemodynamic Function at Six Months After Successful TPV Implantation</title>
          <description>Acceptable TPV hemodynamic function at six months after successful TPV implantation is determined as a composite of the following:
Mean RVOT gradient is less than or equal to 30 mmHg as measured by CW Doppler, and
Severity of pulmonary regurgitation is less than moderate by Doppler echocardiography, and
Free from RVOT conduit reoperation or catheter re-intervention at six months after TPV implantation.
The endpoint is defined as the percentage of subjects with acceptable TPV hemodynamic function at six months after Melody valve implantation.</description>
          <population>The implanted &gt;24 hours cohort consists of all subjects who had a Melody TPV implanted which remained implanted for greater than 24 hours. Of this population those with evaluable echo data at 6 months post implant were included in the analysis.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.7" lower_limit="91.6" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedural Success</title>
        <description>Procedural success is defined as a composite of the following:
The TPV is fixated within the desired location, and
The RV-PA peak-to-peak gradient measured in the catheterization lab after TPV implantation is less than 35 mmHg, and
There is no more than trivial pulmonary regurgitation by angiography
The subject is free from explantation of the TPV at 24 hours post-implant</description>
        <time_frame>6 Months</time_frame>
        <population>The attempted implant cohort consists of all subjects who underwent catheterization and a Melody TPV implantation was attempted (Melody TPV valve opened).</population>
        <group_list>
          <group group_id="O1">
            <title>Attempted Implant Cohort</title>
            <description>The attempted implant cohort consists of all subjects who underwent catheterization and a Melody TPV implantation was attempted (Melody TPV valve opened).</description>
          </group>
        </group_list>
        <measure>
          <title>Procedural Success</title>
          <description>Procedural success is defined as a composite of the following:
The TPV is fixated within the desired location, and
The RV-PA peak-to-peak gradient measured in the catheterization lab after TPV implantation is less than 35 mmHg, and
There is no more than trivial pulmonary regurgitation by angiography
The subject is free from explantation of the TPV at 24 hours post-implant</description>
          <population>The attempted implant cohort consists of all subjects who underwent catheterization and a Melody TPV implantation was attempted (Melody TPV valve opened).</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Procedural Adverse Events</title>
        <description>A procedure-related event is defined as an event that is associated with the implant procedure by the chronology or physiology and was caused by the implant procedure (e.g. rupture of the conduit or damage to an intra-cardiac or intravascular structure by the delivery system).</description>
        <time_frame>6 Months</time_frame>
        <population>The catheterized cohort consists of all subjects who underwent catheterization for possible implantation of the Melody TPV.</population>
        <group_list>
          <group group_id="O1">
            <title>Catheterized Cohort</title>
            <description>The catheterized cohort consists of all subjects who underwent catheterization for possible implantation of the Melody TPV.</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Procedural Adverse Events</title>
          <description>A procedure-related event is defined as an event that is associated with the implant procedure by the chronology or physiology and was caused by the implant procedure (e.g. rupture of the conduit or damage to an intra-cardiac or intravascular structure by the delivery system).</description>
          <population>The catheterized cohort consists of all subjects who underwent catheterization for possible implantation of the Melody TPV.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Device-related Adverse Events</title>
        <description>A device-related event is defined as an event that is associated with the TPV by the chronology or physiology and was caused by the the TPV (e.g. embolization of the TPV and any adverse events which follow).</description>
        <time_frame>6 months</time_frame>
        <population>The implanted cohort consists of all subjects who underwent catheterization and a Melody TPV was implanted.</population>
        <group_list>
          <group group_id="O1">
            <title>Implanted Cohort</title>
            <description>The implanted cohort consists of all subjects who underwent catheterization and a Melody TPV was implanted.</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Device-related Adverse Events</title>
          <description>A device-related event is defined as an event that is associated with the TPV by the chronology or physiology and was caused by the the TPV (e.g. embolization of the TPV and any adverse events which follow).</description>
          <population>The implanted cohort consists of all subjects who underwent catheterization and a Melody TPV was implanted.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in NYHA Functional Classification</title>
        <description>Change in NYHA functional class from pre-implant to 6 month post-implant</description>
        <time_frame>6 Months</time_frame>
        <population>The implanted &gt;24 hours cohort consists of all subjects who had a Melody TPV implanted which remained implanted for greater than 24 hours. Of this population those with evaluable paired NYHA data were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Implanted &gt; 24 Hours Cohort</title>
            <description>The implanted &gt;24 hours cohort consists of all subjects who had a Melody TPV implanted which remained implanted for greater than 24 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in NYHA Functional Classification</title>
          <description>Change in NYHA functional class from pre-implant to 6 month post-implant</description>
          <population>The implanted &gt;24 hours cohort consists of all subjects who had a Melody TPV implanted which remained implanted for greater than 24 hours. Of this population those with evaluable paired NYHA data were included in the analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Changes in NYHA Functional Classification</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Catheterized Cohort</title>
          <description>The catheterized cohort consists of all subjects who underwent catheterization for possible implantation of the Melody TPV.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemias NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Haematological disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Coronary artery disorders NEC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Pulmonary valvular disorders</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Rate and rhythm disorders NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Supraventricular arrhythmias</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmias and cardiac arrest</sub_title>
                <counts group_id="E1" events="9" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders NEC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Nausea and vomiting symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>diarrhoea (excl infective)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Device issues NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Device physical property and chemical issues</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Febrile disorders</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Therapeutic and nontherapeutic responses</sub_title>
                <counts group_id="E1" events="9" subjects_affected="4" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cardiac infections</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract and lung infections</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Sepsis, bacteraemia, viraemia and fungaemia NEC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cardiac and vascular procedural complications</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Non-site specific procedural complications</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders NEC</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Neurological signs and symptoms NEC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax and pleural effusions NEC</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Pulmonary thrombotic and embolic conditions</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Respiratory tract disorders NEC</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Non-site specific embolism and thrombosis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Vascular injuries NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain and discomfort NEC</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Therapeutic and nontherapeutic responses</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections NEC</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Non-site specific procedural complications</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A publication committee is in place for this study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Susan Patterson</name_or_title>
      <organization>Medtronic</organization>
      <phone>763.526.1544</phone>
      <email>susan.patterson@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

